1-15 of 248
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS
Chandrikha Chandrasekharan, MBBS
How KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Clinician's RoundtableHow KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Brian P. McDonough, MD, FAAFP
Thanai Pongdee, MD
Improving Diagnostic Accuracy in Systemic Mastocytosis
Clinician's RoundtableImproving Diagnostic Accuracy in Systemic Mastocytosis
Alexandria May, PharmD, BCPS
Tracy George, MD
Breaking Barriers in Familial Chylomicronemia Syndrome
On the Frontlines of Familial Chylomicronemia SyndromeBreaking Barriers in Familial Chylomicronemia Syndrome
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Robert Hegele MD, FRCPC
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
NeuroFrontiersRecognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Alexandria May, PharmD, BCPS
Kaitlin Batley, MD
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiersIdentifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP
Bethany Lussier, MD
- advertisement
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
On the Frontlines of Familial Chylomicronemia SyndromeCardiometabolic Considerations in Familial Chylomicronemia Syndrome
Steve Jackson, PharmD
Robert H. Eckel, MD, FAHA, FACC, FNLA
Advancing Long-Term Outcomes in Systemic Mastocytosis: The Latest Research
Clinician's RoundtableAdvancing Long-Term Outcomes in Systemic Mastocytosis: The Latest Research
Charles Turck, PharmD, BCPS, BCCCP
Anthony Hunter, MD
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Project Oncology®Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP
Petros Grivas, MD, PhD
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Project Oncology®ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Charles Turck, PharmD, BCPS, BCCCP
Guru P. Sonpavde, MD
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiersExamining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP
Austin Larson, MD
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiersUnpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
- advertisement
ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Project Oncology®ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Charles Turck, PharmD, BCPS, BCCCP
Pooja Ghatalia, MD
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstractsIntegrating CMR and Genetics to Improve ATTR-CM Diagnosis
Ryan Quigley
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CMRNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD
Chadi Alraies, MD, MPH, FACC
